RxDoctor Payments Data

Naseeruddin Khan, MD

Nephrology · Baton Rouge, LANPI 1912954496

Payments from drug & device makers

$1,857in general payments, 2019–2025

Across 68 payments — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$500
  • Aurinia Pharma U.S., Inc.$224
  • Vifor Pharma, Inc.$191
  • AstraZeneca$170
  • Bayer$149
  • Baxter Healthcare$118
  • plus $505 from 12 others

What the payments were for

  • Food & beverage$1,74894%
  • Education$1096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,857 in reported general payments places this provider in the 45th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$187,189
Medicare patients
236
Services billed
1,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LivtencityMaribavir23$570,139
NulojixBelatacept34$84,631
LokelmaSodium Zirconium Cyclosilicate86$76,549
JardianceEmpagliflozin80$59,209
OzempicSemaglutide42$45,445
FarxigaDapagliflozin Propanediol45$35,992
EliquisApixaban36$28,599
Valganciclovir Hcl126$28,028
TradjentaLinagliptin33$24,861
Cinacalcet Hcl64$24,364
TrulicityDulaglutide19$17,723
VeltassaPatiromer Calcium Sorbitex17$16,739
Mycophenolic AcidMycophenolate Sodium40$13,105
Tacrolimus39$11,370
LinzessLinaclotide20$10,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$170$112,541131 claims
Novo NordiskOzempic$93$45,44542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →